Big Pharma R&D veteran with blockbuster credentials returns to his biotech roots as Prothena's new CMO
In 2018, Prothena CMO Sarah Noonberg left the company after just nine months on the job, later popping up at Nohla Therapeutics. Now, nearly three years later, Prothena has tapped someone to fill her empty role.
Neuroscience expert Hideki Garren joined Prothena’s South San Francisco team on Monday, just three days after leaving his post as Genentech’s VP and global head of neuroimmunology. The Big Pharma veteran — who led Roche’s Phase III programs for its blockbuster MS drug Ocrevus — told Endpoints News he was attracted by the opportunity to return to his roots at a small biotech.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.